Study identifier:D5130L00065
ClinicalTrials.gov identifier:NCT02052635
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase IV, Randomised, Multi-Centre, Open label Study, Comparing ticagrelor versus clopidogrel in non-ST elevation acute coronary syndrome (NSTE-ACS) patients undergoing percutaneous coronary intervention (PCI) with bivalirudin
Non-ST elevation Acute Coronary Syndrome
Phase 4
No
ticagrelor, clopidogrel
All
34
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: Pharmacodynamics
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Apr 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Ticagrelor 90 mg oral tablet | Drug: ticagrelor Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact. Other Name: Brilinta |
Active Comparator: Clopidogrel 300 mg oral tablet | Drug: clopidogrel Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact. Other Name: Plavix |